Skip to content

Clinical trials

Pulmonary Disease, Chronic Obstructive trials in China with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pulmonary Disease, Chronic Obstructive Status: Unknown status Country / region: China Clear all

112 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20071
20091
20101
20121
20136
20148
20152
20165
201718
20186
201912
20207
202116
20228
202317
20243

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status112

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Chinese Academy of Medical Sciences, Fuwai Hospital8
The First Affiliated Hospital of Guangzhou Medical University8
Henan University of Traditional Chinese Medicine7
China-Japan Friendship Hospital6
Guangzhou Institute of Respiratory Disease6
Peking University Third Hospital6
Zhujiang Hospital6
Zhejiang Chinese Medical University5
Chinese PLA General Hospital4
Beijing Chao Yang Hospital3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pulmonary Disease, Chronic Obstructive112
Respiratory Insufficiency8
Bronchitis, Chronic5
Asthma4
Anxiety Disorders3
Bronchiectasis3
COVID-193
Hypertension, Pulmonary3
Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome2
Emphysema2

Trials

Showing 1 to 25 of 112. Each trial links to its page on Pharma Observatory.

12 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.